Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2016 | 1 |
2017 | 2 |
2018 | 2 |
2020 | 2 |
2024 | 0 |
Search Results
7 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Correction: Antoniou, M.; et al. Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review. J. Pers. Med. 2017, 7, 1.
J Pers Med. 2018 May 7;8(2):17. doi: 10.3390/jpm8020017.
J Pers Med. 2018.
PMID: 29735910
Free PMC article.
No abstract available.
Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.
Antoniou M, Kolamunnage-Dona R, Jorgensen AL.
Antoniou M, et al.
J Pers Med. 2017 Jan 25;7(1):1. doi: 10.3390/jpm7010001.
J Pers Med. 2017.
PMID: 28125057
Free PMC article.
Review.
Item in Clipboard
Correction: Antoniou, M.; et al. Fixed and Adaptive Parallel Subgroup-Specific Design for Survival Outcomes: Power and Sample Size. J. Pers. Med. 2017, 7, 19.
Antoniou M, Jorgensen AL, Kolamunnage-Dona R.
Antoniou M, et al.
J Pers Med. 2018 May 7;8(2):18. doi: 10.3390/jpm8020018.
J Pers Med. 2018.
PMID: 29735935
Free PMC article.
No abstract available.
Item in Clipboard
Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.
Antoniou M, Jorgensen AL, Kolamunnage-Dona R.
Antoniou M, et al.
PLoS One. 2016 Feb 24;11(2):e0149803. doi: 10.1371/journal.pone.0149803. eCollection 2016.
PLoS One. 2016.
PMID: 26910238
Free PMC article.
Review.
Item in Clipboard
Matching-adjusted indirect comparison: entrectinib versus crizotinib in ROS1 fusion-positive non-small cell lung cancer.
Chu P, Antoniou M, Bhutani MK, Aziez A, Daigl M.
Chu P, et al. Among authors: antoniou m.
J Comp Eff Res. 2020 Aug;9(12):861-876. doi: 10.2217/cer-2020-0063. Epub 2020 Jul 10.
J Comp Eff Res. 2020.
PMID: 32648475
Free article.
Item in Clipboard
Fixed and Adaptive Parallel Subgroup-Specific Design for Survival Outcomes: Power and Sample Size.
Antoniou M, Jorgensen AL, Kolamunnage-Dona R.
Antoniou M, et al.
J Pers Med. 2017 Dec 4;7(4):19. doi: 10.3390/jpm7040019.
J Pers Med. 2017.
PMID: 29207572
Free PMC article.
Item in Clipboard
A RESPONSE TO "THE POTENTIAL LONG-TERM COMPARATIVE EFFECTIVENESS OF LAROTRECTINIB AND ENTRECTINIB FOR SECOND-LINE TREATMENT OF TRK FUSION-POSITIVE METASTATIC LUNG CANCER".
Ogale S, Zerbini CEH, Antoniou M, Freund R.
Ogale S, et al. Among authors: antoniou m.
J Manag Care Spec Pharm. 2020 Dec;26(12):1616-1617. doi: 10.18553/jmcp.2020.26.12.1616.
J Manag Care Spec Pharm. 2020.
PMID: 33251994
Free PMC article.
Item in Clipboard
Cite
Cite